Literature DB >> 21450977

A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.

Lesley C Dupuy1, Michelle J Richards, Barry Ellefsen, Lillian Chau, Alain Luxembourg, Drew Hannaman, Brian D Livingston, Connie S Schmaljohn.   

Abstract

We evaluated the immunogenicity and protective efficacy of a DNA vaccine expressing codon-optimized envelope glycoprotein genes of Venezuelan equine encephalitis virus (VEEV) when delivered by intramuscular electroporation. Mice vaccinated with the DNA vaccine developed robust VEEV-neutralizing antibody responses that were comparable to those observed after administration of the live-attenuated VEEV vaccine TC-83 and were completely protected from a lethal aerosol VEEV challenge. The DNA vaccine also elicited strong neutralizing antibody responses in rabbits that persisted at high levels for at least 6 months and could be boosted by a single additional electroporation administration of the DNA performed approximately 6 months after the initial vaccinations. Cynomolgus macaques that received the vaccine by intramuscular electroporation developed substantial neutralizing antibody responses and after an aerosol challenge had no detectable serum viremia and had reduced febrile reactions, lymphopenia, and clinical signs of disease compared to those of negative-control macaques. Taken together, our results demonstrate that this DNA vaccine provides a potent means of protecting against VEEV infections and represents an attractive candidate for further development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21450977      PMCID: PMC3122536          DOI: 10.1128/CVI.00030-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  49 in total

Review 1.  Clinical recognition and management of patients exposed to biological warfare agents.

Authors:  D R Franz; P B Jahrling; D J McClain; D L Hoover; W R Byrne; J A Pavlin; G W Christopher; T J Cieslak; A M Friedlander; E M Eitzen
Journal:  Clin Lab Med       Date:  2001-09       Impact factor: 1.935

Review 2.  Bioterrorism.

Authors:  M G Kortepeter; T J Cieslak; E M Eitzen
Journal:  J Environ Health       Date:  2001 Jan-Feb       Impact factor: 1.179

Review 3.  Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments.

Authors:  Angela M Bodles-Brakhop; Richard Heller; Ruxandra Draghia-Akli
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

4.  Venezuelan equine Encephalitis virus capsid protein forms a tetrameric complex with CRM1 and importin alpha/beta that obstructs nuclear pore complex function.

Authors:  Svetlana Atasheva; Alexander Fish; Maarten Fornerod; Elena I Frolova
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

5.  T cells facilitate recovery from Venezuelan equine encephalitis virus-induced encephalomyelitis in the absence of antibody.

Authors:  Christopher B Brooke; Damon J Deming; Alan C Whitmore; Laura J White; Robert E Johnston
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

6.  Detection of individual mouse splenic T cells producing IFN-gamma and IL-5 using the enzyme-linked immunospot (ELISPOT) assay.

Authors:  T Taguchi; J R McGhee; R L Coffman; K W Beagley; J H Eldridge; K Takatsu; H Kiyono
Journal:  J Immunol Methods       Date:  1990-03-27       Impact factor: 2.303

7.  Onset and duration of protective immunity to IA/IB and IE strains of Venezuelan equine encephalitis virus in vaccinated mice.

Authors:  M K Hart; C Lind; R Bakken; M Robertson; R Tammariello; G V Ludwig
Journal:  Vaccine       Date:  2001-11-12       Impact factor: 3.641

8.  Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus.

Authors:  R J Phillpotts; L D Jones; S C Howard
Journal:  Vaccine       Date:  2002-02-22       Impact factor: 3.641

Review 9.  Electroporation advances in large animals.

Authors:  Scott D Reed; Shulin Li
Journal:  Curr Gene Ther       Date:  2009-08       Impact factor: 4.391

10.  Immunogenicity in mice and rabbits of DNA vaccines expressing woodchuck hepatitis virus antigens.

Authors:  Alain Luxembourg; Drew Hannaman; Ken Wills; Robert Bernard; Bud C Tennant; Stephan Menne; Paul J Cote
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

View more
  28 in total

Review 1.  DNA-launched live-attenuated vaccines for biodefense applications.

Authors:  Peter Pushko; Igor S Lukashevich; Scott C Weaver; Irina Tretyakova
Journal:  Expert Rev Vaccines       Date:  2016-04-25       Impact factor: 5.217

2.  Venezuelan equine encephalitis virus variants lacking transcription inhibitory functions demonstrate highly attenuated phenotype.

Authors:  Svetlana Atasheva; Dal Young Kim; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

Review 3.  An Overview of Animal Models for Arthropod-Borne Viruses.

Authors:  Erin S Reynolds; Charles E Hart; Meghan E Hermance; Douglas L Brining; Saravanan Thangamani
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

4.  Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges.

Authors:  Rebecca J Grant-Klein; Louis A Altamura; Catherine V Badger; Callie E Bounds; Nicole M Van Deusen; Steven A Kwilas; Hong A Vu; Kelly L Warfield; Jay W Hooper; Drew Hannaman; Lesley C Dupuy; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Authors:  Douglas S Reed; Pamela J Glass; Russell R Bakken; James F Barth; Cathleen M Lind; Luis da Silva; Mary Kate Hart; Jonathan Rayner; Kim Alterson; Max Custer; Jeanne Dudek; Gary Owens; Kurt I Kamrud; Michael D Parker; Jonathan Smith
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

6.  Current strategic thinking for the development of a trivalent alphavirus vaccine for human use.

Authors:  Daniel N Wolfe; D Gray Heppner; Shea N Gardner; Crystal Jaing; Lesley C Dupuy; Connie S Schmaljohn; Kevin Carlton
Journal:  Am J Trop Med Hyg       Date:  2014-05-19       Impact factor: 2.345

Review 7.  Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.

Authors:  John J Suschak; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452

8.  Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.

Authors:  Marcelo M Samsa; Lesley C Dupuy; Clayton W Beard; Carolyn M Six; Connie S Schmaljohn; Peter W Mason; Andrew J Geall; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-01-07       Impact factor: 11.454

9.  Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine.

Authors:  Irina Tretyakova; Igor S Lukashevich; Pamela Glass; Eryu Wang; Scott Weaver; Peter Pushko
Journal:  Vaccine       Date:  2012-12-31       Impact factor: 3.641

10.  A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge.

Authors:  Rebecca J Grant-Klein; Nicole M Van Deusen; Catherine V Badger; Drew Hannaman; Lesley C Dupuy; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.